Background: Atrial fibrillation (AF) is associated with considerable morbidity and mortality. Timely management and treatment is critical in alleviating AF disease burden. Variation in treatment by race and ethnic and sex could lead to inequities in health outcomes., Objective: To identify racial and ethnic and sex differences in rhythm treatment for patients with incident AF., Methods: Using 2010-2019 Optum Clinformatics database, an administrative claims data for commercially insured patients in the United States (US), incident AF patients ≥20 years old who were continuously enrolled 12-months pre- and post-index diagnosis were identified. Rhythm control treatment (ablation, antiarrhythmic drugs [AAD], and cardioversion) for AF were compared by patient race and ethnicity (Asian, Hispanic, Black vs White) and sex (female vs male). Multivariable regression analysis was used to examine the relationship of race and ethnicity and sex with rhythm control AF treatment., Results: A total of 77,932 patients were identified with incident AF. Black and Hispanic female patients had the highest CHA 2 DS 2 VASc scores (4.3 ± 1.8) and Elixhauser scores (4.1 ± 2.8 and 4.0 ± 6.7), respectively. Black males were less likely to receive AAD treatment (adjusted odds ratio [aOR] 0.87; 95% confidence interval [CI], 0.79-0.96) or ablation (aOR, 0.72; 95% CI, 0.58-0.90). Compared to White males, all groups had lower likelihood of receiving cardioversion with Asian females having the lowest [aOR, 0.48; 95% CI, (0.37-0.63)]., Conclusion: Black patients were less likely to receive pharmacologic and procedural rhythm control therapies. Further research is needed to understand the drivers of undertreatment among racial and ethnic groups and females with AF., Competing Interests: Diane M Francis, Sonia Maccioni, Vincent C Thomas, Paul Coplan, Rahul Khanna, Charlene Wong, and Neloufar Rahai are Johnson & Johnson employees. Dr Larry R Jackson II has received: research grants from the National Institute of Health, specifically the National Institute on Minority Health and Health Disparities. Dr Jackson is currently supported by 1K01HL159041 from the National Heart, Lung and Blood Institute and the American Association under award number 851386 and serves as a consultant to Biosense Webster, Johnson & Johnson, Sanofi, Bristol Myers Squibb and Pfizer and receives honoraria from Zoll LifeVest, CME outfitters, Health Monitor, PRIME Education, and WebMD/Medscape. Dr Friedman has received research grants from the American Heart Association, National Cardiovascular Data Registry, Boston Scientific, Abbott, Medtronic, Merit Medical, and Biosense Webster and consulting fees from Abbott, AtriCure, and Sanofi. Dr Jonathan P Piccini is supported by R01HL128595 from the National Heart, Lung and Blood Institute and receives grants for clinical research from Abbott, American Heart Association, Association for the Advancement of Medical Instrumentation, Bayer, Boston Scientific, National Institutes of Health, and Philips and serves as a consultant to Abbott, AbbVie, Ablacon, Altathera, ARCA Biopharma, Biotronik, Boston Scientific, Bristol Myers Squibb, LivaNova, Medtronic, Milestone, ElectroPhysiology Frontiers, Itamar, Pfizer, Sanofi, Philips, ResMed, and Up-to-Date. The authors report no other conflicts of interest in this work., (© 2023 Jackson II et al.)